$FEMY

Canning John Charles purchased $14K of FEMY

Canning John Charles (Chief Operating Officer) purchased 4,375 shares of FEMASYS INC (FEMY) at $3.20 on 2026-08-07.

Original reporting
SEC EDGAR · Canning John Charles
Published Aug 12, 2026, 12:40 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 12, 2026, 1:04 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$FEMY
Bullish
medium confidence
Mentioned
$FEMY
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$FEMYBullishLow
01

Why it matters

The only new fact is the insider’s open-market purchase details; there is no accompanying operational or financial update.

02

Market read

Traders may note the insider buying, but the disclosed size is small and lacks fundamental catalysts.

03

What to watch

The filing does not state motivations, and the transaction lacks a 10b5-1 plan, which can increase noise rather than clarity.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-11 after trade on 2026-08-07

Background

The article is an SEC Form 4 insider transaction disclosure for FEMASYS Inc.

Company-level read

Ticker impact

$FEMYBullishMedium confidence
Context

SEC Form 4 shows COO Canning John Charles bought 4,375 shares of FEMASYS at $3.20 on 2026-08-07, totaling about $14,000.

Expected impact

Low likelihood of a sustained price move; any reaction would be limited and short-lived.

Evidence & confidence

The disclosure is a routine Form 4 insider transaction with modest dollar value and no 10b5-1 plan, but it does not include new company performance, guidance, or material corporate events.

Market effects

No sector-level implications are disclosed; this is company-specific insider activity only.

None indicated.

None indicated.

Counterpoint

Insider buys can be opportunistic and do not necessarily signal improved fundamentals, especially at small sizes.

Key entities

  • FEMASYS Inc

    Company whose insider transaction is disclosed on Form 4.

  • Canning John Charles

    Chief Operating Officer who purchased shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GILDMedAI 8/10

Weekly Buzz: Gilead Sciences, Roivant Sciences Win FDA Nod; Biohaven, Eli Lilly Strike Deal; Spyre Therapeutics Misses Monotherapy Goal

Gilead (GILD) and Roivant (ROIV) received FDA approvals for Bixlenvo and LISRAYA, respectively. Johnson & Johnson (JNJ) also gained approval for IMAAVY. Biohaven (BHVN) and Eli Lilly (LLY) advanced partnerships. Spyre Therapeutics missed a clinical trial goal. Key stocks: GILD +0.52%, ROIV +2.26%, JNJ -1.57%.

$FEMYMed

FEMASYS INC (FEMY): Results of Operations and Financial Condition

FEMASYS INC (FEMY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update -- $30 million financing enables execution of U.S. commercial strategy for the FemaSeed ® fertility portfolio and advancement of the FemBloc ® clinical and regulatory pr

$FEMYMedAI 8/10

Femasys Stock Falls 11% Over Announcement Of $30 Mln Private Placement

Femasys Inc. (FEMY) shares fell 11.07% to $2.65 after the company announced a $30 million private placement on Nasdaq. Femasys will sell 9.37 million shares plus pre-funded warrants and warrants for 18.75 million shares, priced at $3.20. Lead investor is Nantahala Capital, with others including Rosalind Advisors. Potential extra cash proceeds up to $60 million if warrants are exercised.

$FEMYMedAI 8/10

Femasys Inc.: Femasys Secures $30 Million Private Placement, with Potential Proceeds of Up to $90 Million

Femasys Inc. (NASDAQ: FEMY) said it entered a $30 million private placement with accredited investors led by Nantahala Capital, with participation from other healthcare funds and management. It will sell 9,374,999 shares plus pre-funded and accompanying warrants. If all warrants are exercised, Femasys could receive up to $60 million more. Closing is expected around Aug. 10, 2026.